Oncology Brothers: Practice-Changing Cancer Discussions
Oncology Brothers
The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients.Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities.If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com
Privacy Policy: https://oncbrothers.com/privacy-policy
Terms & Conditions: https://oncbrothers.com/terms-and-conditions
Privacy Policy: https://oncbrothers.com/privacy-policy
Terms & Conditions: https://oncbrothers.com/terms-and-conditions
Episodes
Mentioned books
Nov 17, 2025 • 20min
FDA Approval of Ziftomenib (KOMET-001) in NPM1 mut Acute Myeloid Leukemia (AML) – Dr. Eunice Wang
Dr. Eunice Wang, a leading hematologist-oncologist at Roswell Park Comprehensive Cancer Center, shares her expertise on the recent FDA approval of Ziftomenib for NPM1-mutant acute myeloid leukemia (AML). She discusses the promising results from the KOMET-001 trial, highlighting a nearly 30% response rate and improved survival for patients. Dr. Wang dives into the mechanism of action of menin inhibitors, management of side effects, and the importance of patient sequencing. She also contrasts Ziftomenib with other treatments, paving the way for future therapies.
Nov 13, 2025 • 16min
Managing Toxicities of ROS1 Inhibitors in Non-Small Cell Lung Cancer (NSCLC) – Dr. Estela Rodriguez
Join Dr. Estela Rodriguez, a thoracic oncologist at Sylvester Comprehensive Cancer Center, as she unpacks the nuances of managing ROS1 fusion positive non-small cell lung cancer. Discover the vital role of comprehensive NGS in treatment planning, and delve into the insights on various tyrosine kinase inhibitors like crizotinib and repotrectinib. Estela highlights common side effects, effective management strategies for toxicities, and the critical importance of patient education and regular follow-ups in optimizing care.
Nov 10, 2025 • 22min
Managing Toxicities of Tyrosine Kinase Inhibitors (TKI) in CML - Drs. Onyee Chan & Fadi Haddad
This discussion features Dr. Fadi Haddad, a hematologist-oncologist specializing in chronic myeloid leukemia (CML) and TKI management, alongside Dr. Onyee Chan, an expert in CML toxicities and patient counseling. They explore the various generations of tyrosine kinase inhibitors and their class-wide toxicities. Key topics include unique side effects of each TKI, strategies for dose optimization, and the critical role of patient education in managing complications effectively. They also delve into specific drug issues, including dasatinib monitoring and bosutinib's GI side effects.
Nov 6, 2025 • 25min
Lung Cancer ESMO 2025 Highlights: MDT-BRIDGE, FLAURA2, SOHO-01, Beamion LUNG-1
Dr. Rami Manochakian, a thoracic oncologist from the Mayo Clinic, shares groundbreaking insights from ESMO 2025 on lung cancer. He highlights the significance of the MDT-BRIDGE trial, which showcases a multidisciplinary approach for non-small cell lung cancer. The conversation dives into the FLAURA2 study, showing survival benefits of osimertinib with chemotherapy. Plus, he introduces promising HER2-targeted therapies like Zongertinib and Sevabertinib, emphasizing the need for upfront NGS testing to personalize treatment strategies.
Nov 3, 2025 • 19min
GI Cancer ESMO 2025 Highlights: DYNAMIC-III, PEGASUS, STELLAR-303, MATTERHORN, FORTITUDE-101
Dr. Rachna Shroff, a GI medical oncologist at the University of Arizona, shares her insights on groundbreaking gastrointestinal oncology data from ESMO 2025. She dives into the potential of ctDNA as a prognostic tool in early-stage colon cancer, and discusses the promising outcomes of immunotherapy for refractory colorectal cancer. The conversation highlights how combining durvalumab with FLOT could redefine upper GI cancer treatment and explores the implications of targeting FGFR2b in metastatic conditions. A must-listen for oncology enthusiasts!
Oct 30, 2025 • 22min
Breast Cancer ESMO 2025 Highlights: MonarchE, NATALEE, VIKTORIA1, evERA, DESTINY, ASCENT, TROPION
Dr. Virginia Kaklamani, a breast medical oncologist from UT San Antonio specializing in clinical trials, shares crucial insights on ESMO 2025 breast cancer data. She discusses breakthrough findings from the MonarchE and NATALEE studies, emphasizing the overall survival benefits of abemaciclib. The conversation dives into the VIKTORIA1 trial results for metastatic HR+ disease and examines the promising efficacy of TDXd in HER2+ breast cancer settings. Kaklamani also addresses treatment strategies for triple negative breast cancer, offering community oncologists practical takeaways.
Oct 27, 2025 • 15min
Current Treatment Landscape of Ovarian Cancer with Dr. Sharyn Lewin
Dr. Sharyn Lewin, a leading gynecologic oncologist and Director of Gynecologic Oncology at Holy Name Medical Center, shares her expertise on ovarian cancer treatments. She emphasizes the critical role of surgical staging and debulking surgeries. The conversation includes insights on germline testing and the use of PARP inhibitors alongside bevacizumab. Dr. Lewin also discusses strategies for managing refractory disease and the importance of biomarker testing, particularly HRD status, for personalized treatment options.
Oct 23, 2025 • 23min
GU Cancer ESMO 2025 Highlights: PSMAddition, Capitello-281, Potomac, Keynote-905, IMVigor011
Dr. Stephanie Berg, a GU medical oncologist from Dana-Farber Cancer Institute, shares insights on groundbreaking cancer studies presented at ESMO 2025. She discusses the promising impact of lutetium PSMA in prostate cancer and highlights the effectiveness of capivasertib for patients with PTEN loss. The conversation also touches on the combination of durvalumab and BCG for high-risk bladder cancer, alongside innovative ctDNA-guided therapies improving survival rates. Tune in for a deep dive into the complexities of cancer treatment and patient-centered care!
Oct 20, 2025 • 18min
Challenging Cases with Metastatic EGFR Mutated Non-Small Cell Lung Cancer with Dr. Eric Singhi
Dr. Eric Singhi, a thoracic medical oncologist from MD Anderson, shares his expertise on treating EGFR-mutated non-small cell lung cancer. He delves into groundbreaking trials like MARIPOSA and FLAURA2, revealing essential insights into treatment strategies and patient management. The discussion includes real-life patient cases, the significance of repeat tissue profiling, and approaches to manage side effects. Singhi emphasizes the role of multidisciplinary teams and the need to understand resistance patterns for effective treatment planning.
Oct 16, 2025 • 22min
Managing Toxicities of CDK4/6 Inhibitors in Hormone Positive Breast Cancer - Dr. Stephanie Graff
Dr. Stephanie Graff, a medical breast oncologist at Brown University Health, dives into the management of CDK4/6 inhibitor toxicities in hormone receptor-positive breast cancer. She discusses critical side effects of ribociclib, abemaciclib, and palbociclib, emphasizing the importance of shared decision-making with patients. Graff covers monitoring techniques, like EKGs for QT prolongation, and practical strategies for managing diarrhea and neutropenia. The insights shared make this a must-listen for anyone involved in cancer care.
